Trial · NCT02184572
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination | INV_MMR Group | > 39.0°C | 47 | Participants | |
| Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination | COM_MMR Group | > 39.0°C | 17 | Participants | |
| Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination | INV_MMR Group | ≥ 38.0°C | 205 | Participants | |
| Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination | COM_MMR Group | ≥ 38.0°C | 95 | Participants | |
| Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value | INV_MMR Group | ≥ 150 mIU/mL | 99.3 | 95% Confidence Interval 98.6 to 99.7 | Percentage of subjects |
| Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value | COM_MMR Group | ≥ 150 mIU/mL | 96.7 | 95% Confidence Interval 94.8 to 98.1 | Percentage of subjects |
| Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value | INV_MMR Group | ≥ 200 mIU/mL | 99.0 | 95% Confidence Interval 98.2 to 99.5 | Percentage of subjects |
| Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value | COM_MMR Group | ≥ 200 mIU/mL | 96.5 | 95% Confidence Interval 94.6 to 97.9 | Percentage of subjects |
| Anti-measles Virus Antibody Concentrations | INV_MMR Group | 2751.9 | 95% Confidence Interval 2618.3 to 2892.2 | mIU/mL | |
| Anti-measles Virus Antibody Concentrations | COM_MMR Group | 3133.3 | 95% Confidence Interval 2878.6 to 3410.6 | mIU/mL | |
| Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value | INV_MMR Group | ≥ 5 EU/mL | 99.8 | 95% Confidence Interval 99.3 to 100 | Percentage of subjects |
| Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value | COM_MMR Group | ≥ 5 EU/mL | 99.4 | 95% Confidence Interval 98.2 to 99.9 | Percentage of subjects |
| Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value | INV_MMR Group | ≥ 10 EU/mL | 99.4 | 95% Confidence Interval 98.7 to 99.8 | Percentage of subjects |
| Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value | COM_MMR Group | ≥ 10 EU/mL | 97.9 | 95% Confidence Interval 96.2 to 99.0 | Percentage of subjects |
| Anti-mumps Virus Antibody Concentrations | INV_MMR Group | 86.0 | 95% Confidence Interval 82.0 to 90.3 | EU/mL | |
| Anti-mumps Virus Antibody Concentrations | COM_MMR Group | 82.6 | 95% Confidence Interval 76.5 to 89.2 | EU/mL | |
| Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value | INV_MMR Group | ≥4 IU/mL | 99.6 | 95% Confidence Interval 99.0 to 99.9 | Percentage of subjects |
| Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value | COM_MMR Group | ≥4 IU/mL | 99.8 | 95% Confidence Interval 98.9 to 100 | Percentage of subjects |
| Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value | INV_MMR Group | ≥10 IU/mL | 95.7 | 95% Confidence Interval 94.3 to 96.8 | Percentage of subjects |
| Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value | COM_MMR Group | ≥10 IU/mL | 98.3 | 95% Confidence Interval 96.7 to 99.2 | Percentage of subjects |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02184572/results